Switching from Dabigatran to Apixaban
Introduction to Switching
- The American College of Cardiology recommends discontinuing dabigatran and beginning apixaban when the next scheduled dose of dabigatran would be due, with no overlap, no gap, and no bridging anticoagulation required 1
- The transition should be seamless with no interruption in anticoagulation coverage, as both agents provide immediate anticoagulant effect once therapeutic levels are reached 1
Dosing Considerations
- For patients with atrial fibrillation, the standard dose of apixaban is 5 mg twice daily 1
- For patients with atrial fibrillation, a reduced dose of 2.5 mg twice daily is recommended if the patient meets at least 2 of the following criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1
- For VTE treatment, the recommended dose is 10 mg twice daily for 7 days, then 5 mg twice daily for continued treatment 1
Key Safety Principles
- Unlike warfarin transitions, concurrent administration with parenteral anticoagulants is not recommended when switching between DOACs 1
- Both dabigatran and apixaban have no cross-reactivity concerns and can be switched directly 4, 5
Special Populations
- For patients with renal impairment, assess creatinine clearance before switching, as both agents require dose adjustment in renal dysfunction 1
- Apixaban is preferred over dabigatran in patients with gastric or gastroesophageal lesions due to lower bleeding risk 1
Common Pitfalls to Avoid
- Never overlap the two DOACs, as this creates excessive anticoagulation and bleeding risk 3
- Do not leave a gap between stopping dabigatran and starting apixaban, as this creates a period of inadequate anticoagulation and thrombotic risk 1
- Avoid assuming all DOACs are interchangeable without dose adjustment, verify the appropriate apixaban dose for the specific indication 1
Drug Interaction Considerations
- Review concomitant medications, particularly P-glycoprotein inhibitors and CYP3A4 inhibitors, which may require apixaban dose adjustment 3